CT screening for lung cancer could save thousands of lives if routinely covered by insurers, according to a Health Affairs study.
CT screening for lung cancer and follow-up care of older long-term smokers could save thousands of lives if routinely covered by insurers, researchers said in a study published in the April issue of Health Affairs.
Bruce Pyenson, an actuary and lead author of the study said that effective screening could significantly affect cancer lung cancer mortality in a cost-effective manner. Unfortunately, most insurance companies do not offer lung cancer screening for high-risk individuals while the costs for treatment are still low if cancer is detected early.
“These results demonstrate the cost efficiency of offering this benefit to people who are at high risk of lung cancer,” said Pyenson. “Late stage lung cancer is deadly, but if treated at an early stage, survival is very good – that’s what makes early detection so promising.”
The first-of-its-kind actuarial study examined the costs and benefits of lung cancer screening using low-dose spiral CT for smokers and long-term former smokers, aged 50 to 64. By modeling insurer costs, assuming about 18 million people were high risk and half would be screened if the benefit was available through private insurance, the researchers found that screening would cost the insurance companies about $246 per member if tested every year. Spread over the commercially insured population, the total screening expense was under $1 per insured person per month.
The researchers estimated that had the screening been available since 1997, 130,000 more people under the age of 65 would be alive today, in addition to more people over 65. The cost per life-year saved would be lower than screening for cervical and breast cancer and comparable to the cost per life-year saved of screening for colorectal cancer, researchers said.
This study follows last year’s published results by the National Cancer Institute, which showed that screening with CT can reduce the risk of dying from lung cancer.
“Rolling out lung cancer screening with embedded continuous quality improvement can prove how care breakthroughs and advanced technology do not have to feed cost escalation,” Pyenson concluded.
The Medical Imaging and Technology Alliance commended the analysis, saying if offers “compelling evidence” that lung cancer screening has the potential to save lives and cost. Gail Rodriguez, MITA’s executive director, said in a statement, “This analysis reinforces the value of advanced medical imaging technologies to improve patient outcomes and drive down health care spending.”
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.